rs121907892 — SLC22A12 W258X

SLC22A12 W258X — When the Uric Acid Gate Breaks Open

Uric acid¹¹ Uric acid
The final breakdown product of purine metabolism in humans. Unlike most mammals, humans lack uricase and cannot degrade uric acid further, so serum levels are tightly regulated by the kidney is a double-edged molecule. High levels cause gout and kidney stones; dangerously low levels, it turns out, carry their own risks. The SLC22A12 gene encodes URAT1 (Urate Transporter 1)²² URAT1 (Urate Transporter 1)
A solute carrier protein in the proximal tubule of the kidney that reabsorbs approximately 90% of filtered uric acid back into the bloodstream. Without it, uric acid spills freely into the urine, the dominant uric acid recapture protein in the kidney. The W258X variant (rs121907892) creates a premature stop codon at position 258, truncating the protein and abolishing its transport function entirely.

The result is renal hypouricemia type 1 (RHUC1)³³ renal hypouricemia type 1 (RHUC1)
A condition defined by a serum uric acid level below 2 mg/dL caused by loss of renal urate reabsorption. Most carriers are asymptomatic but have a measurably increased risk of exercise-induced acute kidney injury — a condition where the kidneys fail to hold onto uric acid, leading to serum levels as low as 0.8 mg/dL in homozygotes. This variant is almost exclusively found in East Asian populations, where it is the most common genetic cause of hypouricemia.

The Mechanism

The URAT1 transporter sits on the apical membrane of proximal tubule cells, facing the filtered urine. Under normal conditions it reabsorbs roughly 90% of urate filtered by the glomerulus. The W258X nonsense mutation — a single G→A substitution at nucleotide 774 of the SLC22A12 coding sequence — introduces a stop codon at amino acid 258, producing a truncated protein that lacks the carboxyl-terminal transmembrane domains essential for membrane targeting and transport activity. The truncated protein is not localized to the cell membrane and is functionally inert.

Toyoda et al. (2021)⁴⁴ Toyoda et al. (2021)
Toyoda Y et al. Substantial anti-gout effect conferred by common and rare dysfunctional variants of URAT1/SLC22A12. Rheumatology (Oxford), 2021 confirmed at the mechanistic level that W258X-truncated URAT1 is not membrane-localized and does not transport urate. Each lost copy reduces serum uric acid substantially, with heterozygotes showing intermediate values and homozygotes reaching near-zero levels.

The Evidence

Komoda et al. (2004)⁵⁵ Komoda et al. (2004)
Komoda F et al. The W258X mutation in SLC22A12 is the predominant cause of Japanese renal hypouricemia. Pediatr Nephrol, 2004 established W258X as the dominant cause of Japanese renal hypouricemia: 11 of 12 identified mutational alleles in 6 of 7 hypouricemia patients were W258X, with 5 patients homozygous and one compound heterozygous.

A cross-sectional study of 5,023 Japanese health examinees⁶⁶ cross-sectional study of 5,023 Japanese health examinees
Hamajima N et al. Serum uric acid distribution according to SLC22A12 W258X genotype in a cross-sectional study of a general Japanese population. BMC Med Genet, 2011 quantified the genotype-phenotype relationship precisely. Males with GG genotype averaged 6.2 mg/dL serum uric acid; heterozygotes (GX) averaged 3.9 mg/dL; the five GG homozygotes averaged just 0.8 mg/dL. The X allele frequency was 2.3% (95% CI: 2.1–2.7%), yielding an estimated XX homozygote prevalence of roughly 1 in 2,000 in Japanese populations.

Sakiyama et al. (2016)⁷⁷ Sakiyama et al. (2016)
Sakiyama M et al. The effects of URAT1/SLC22A12 nonfunctional variants, R90H and W258X, on serum uric acid levels and gout/hyperuricemia progression. Sci Rep, 2016 studied 1,993 gout patients and 4,902 health examinees. W258X was absent in every single gout case. Among health examinees, males carrying one nonfunctional allele had 2.19 mg/dL lower serum uric acid than wild-type; those with two had 5.42 mg/dL lower — an effect so large it completely eliminated hyperuricemia risk (risk ratio 0.036, P = 6.7×10⁻¹⁹ in males).

The darker side of URAT1 loss emerged in studies of exercise-induced acute kidney injury (EIAKI)⁸⁸ exercise-induced acute kidney injury (EIAKI)
AKI occurring hours after intense physical exertion in people with renal hypouricemia. Believed to result from uric acid crystals precipitating in the tubules during the high urine flow and concentration spikes of exercise. Kaito et al. (2013)⁹⁹ Kaito et al. (2013)
Kaito H et al. Molecular background of urate transporter genes in patients with exercise-induced acute kidney injury. Am J Nephrol, 2013 analyzed 17 EIAKI patients: 15 carried SLC22A12 mutations (mostly W258X). All homozygous or compound heterozygous carriers had documented hypouricemia. Critically, impaired transporter function — not merely low serum uric acid — appeared to drive the AKI risk, since some heterozygous carriers with borderline uric acid levels also experienced EIAKI.

Animal evidence from a double knockout mouse model¹⁰¹⁰ double knockout mouse model
Hosoyamada M et al. Urat1-Uox double knockout mice are experimental animal models of renal hypouricemia and exercise-induced acute kidney injury. Nucleosides Nucleotides Nucleic Acids, 2016 confirmed that these mice spontaneously develop exercise-induced AKI, and that allopurinol — by reducing uric acid production upstream — provides prophylactic protection.

Practical Actions

Heterozygous carriers (AG) have intermediate serum uric acid levels — roughly 3.9 mg/dL average in males — which is well within the safe range and confers protection against gout. No specific interventions are required, but awareness of hydration needs during intense exercise is prudent.

Homozygous carriers (AA) face a different calculus. Serum uric acid below 1 mg/dL creates a real risk of exercise-induced AKI: episodes can occur with vigorous activity, typically presenting as flank pain, hematuria, and oliguria within hours of exercise. Prevention centers on avoiding dehydration, moderating intensity, and — in consultation with a nephrologist — potentially considering low-dose allopurinol as prophylaxis during high-intensity training periods.

Homozygotes should also disclose their condition before surgery or procedures involving contrast agents, as the hypouricemic kidney may be more vulnerable to additional acute insults.

Interactions

The W258X variant interacts with the companion SLC22A12 variant R90H (rs147647315), another loss-of-function allele present at low frequency in East Asian populations. Compound heterozygosity for W258X and R90H produces the same full-LOF phenotype as W258X homozygosity. A second urate transporter gene, SLC2A9 (encoding GLUT9), harbors variants that cause renal hypouricemia type 2 — these can produce overlapping phenotypes including EIAKI and should be considered in hypouricemic patients who test negative for SLC22A12 mutations.